Clinical Trial Update: Chronic Anticoagulation With a Reduced Dose Regimen of Rivaroxaban in End-stage Renal Disease Patients [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating a reduced-dose rivaroxaban regimen for chronic anticoagulation in end-stage renal disease patients on chronic hemodialysis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease Requiring Hemodialysis
• End-stage Renal Disease

Drugs mentioned

• Rivaroxaban (rivaroxaban)

Snippet

Sponsor: University Hospital, Tours | Conditions: Chronic Hemodialysis Patients | Phase 3 | Status: UNKNOWN